Ekso Bionics Announces Public Offering Pricing
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), a prominent player in the exoskeleton technology industry for both medical and industrial uses, has recently revealed details about an underwritten public offering. This offering will consist of 6,000,000 units and is projected to raise around $6.0 million in gross proceeds, not accounting for underwriting discounts and other related expenses.
Offering Breakdown
This offering comprises two main components: 3,100,000 units priced at $1.00 each and 2,900,000 pre-funded units available for $0.999 each. Each unit includes one share of common stock and two types of warrants: a Series A Warrant and a Series B Warrant. The Series A Warrant permits the purchase of one share of common stock at an exercise price of $1.00 per share, with a five-year expiration. In contrast, the Series B Warrant also allows for the purchase of one share at the same price but is valid for only one year. Both units and pre-funded units can be separated and issued independently right away.
Planned Use of Proceeds
Ekso Bionics plans to allocate the net proceeds from this offering toward various corporate objectives. These may include expanding the EksoHealth division, particularly as the company aims to boost its revenue following new reimbursement guidelines from healthcare authorities. Additionally, the funds will support ongoing research and development efforts and cover selling, general, and administrative costs. The company is also considering strategic initiatives that might involve advantageous acquisitions. The expected closing date for this offering is September 3, 2024, pending the fulfillment of customary closing conditions.
Offering Management
Craig-Hallum has been appointed as the sole managing underwriter for this public offering. The offering is being carried out under a registration statement that has been approved by regulatory authorities, ensuring adherence to relevant securities laws.
About Ekso Bionics
Ekso Bionics is recognized as a leading innovator in exoskeleton technology, committed to enhancing human capabilities through advanced solutions that improve strength, endurance, and mobility. Established in 2005, the company has continually refined its expertise to develop some of the most advanced wearable robots available today. These technologies are vital in assisting individuals with mobility challenges and enhancing human performance across various job settings worldwide. Headquartered in the San Francisco Bay Area, Ekso Bionics is publicly traded on the Nasdaq Capital Market under the ticker symbol “EKSO.”
Frequently Asked Questions
What is the main purpose of Ekso Bionics’ funding from this offering?
The funds will support corporate initiatives, including expansion of the EksoHealth segment, research and development, and strategic acquisitions.
How many total units are available in this public offering?
There are a total of 6,000,000 units available in this public offering.
Who is managing the public offering for Ekso Bionics?
Craig-Hallum is acting as the sole managing underwriter for this offering.
What are the types of warrants included in the offering?
The offering includes Series A and Series B Warrants, each allowing the purchase of shares at specified exercise prices.
When is the expected closing date for the offering?
The expected closing date for the offering is around September 3, 2024, subject to standard closing conditions.
